Global Erectile Dysfunction Drugs Market To Grow At A CAGR Of 6.9% During The Projection Period.

The global erectile dysfunction drugs market reached nearly USD 3.64 billion in 2021 and is projected to expand with a compound annual growth rate (CAGR) of approximately 6.9 percent over the forecast period to grow by about USD 5.94 billion by 2028.

Erectile dysfunction is the disorderly functioning of the male sex organ and occurs when a man is not able to hold a complete erection during sexual intercourse. As per reports, around 30m men can be affected by erectile dysfunction. Some of the major causes of ED is the limited blood flow toward the male sex organ if there is some harm caused to the nerves, due to rising stress or hormonal levels, and it also acts as an early warning towards more serious diseases like atherosclerosis or heart issues.

Patients who suffer from ED should first be evaluated by certified professionals to determine the exact underlying cause or psychological conditions. In case the treatment of underlying causes is not enough, additional medication or helping devices like pumps can be provided to the patient. Some of the medicines present in the global erectile dysfunction drugs market are vardenafil (Levitra, Staxyn), avanafil (Stendra), Sildenafil (Viagra), and tadalafil (Cialis). These are oral medications and should be consumed only in prescribed dosages to avoid any adverse effects on the body. These drugs act by adding to the effects of nitric oxide which is a natural muscle relaxant.

Covid-19 had a positive impact on the global market as the demand for these drugs increased significantly owing to increased cases of ED amongst men. As per a report published by the University of Miami - Miller School of Science, Florida in 2020, Covid-19 induced endothelial dysfunction led to erectile dysfunction as well.

With advancements in generating awareness about different medical conditions and creating a healthy discussion around topics that were earlier considered taboo, or led to the shaming of patients, there is a rising acceptance of understanding the main causes behind erectile dysfunction and treatment measures. This is also assisted by the increased advertising and marketing campaigns run by private players to generate wakefulness amongst the population. This has caused many ED-affected patients to come out and undergo proper medical consultation and overcome the problem. The rising awareness and general acceptance of the disease are anticipated to aid the global erectile dysfunction drugs market. There is a significant change in lifestyle amongst the population with increasing consumption of alcohol, drugs, frequent smoking habits, surging stress levels, etc. All of these reasons along with growth in obesity index and patients suffering from high blood pressure are leading causes of the increasing ED cases and are anticipated to aid the global market growth in the coming years.

Some of the adverse side effects associated with ED drugs are expected to hinder the global market growth whereas increased pharmaceutical manufacturing in emerging countries is likely to offer better growth opportunities for global market expansion. An increase in the availability of counterfeit erectile dysfunction medicines poses a major challenge for the global market growth.

The global erectile dysfunction drugs market is categorized based on therapeutics and region. By therapeutics, the global erectile dysfunction market is bifurcated into Existing drugs, Tadalafil, Sildenafil Citrate Vardenafil, Udenafil, Stendra/Spedra, Lodenafil Carbonate, Mirodenafil Pipeline drugs, Apomorphine, Alprostadil, Topiglan, Gene Therapy, and Melanocortin Activators.

North America is expected to dominate the global erectile dysfunction drugs market owing to the rising number of ED cases owing to hectic lifestyles, higher consumption of recreational drugs, rise in geriatric population, the excellent healthcare structure in the region, and medical reimbursement policies. As of 2020, around 81% of the global pharmaceutical sector of the global market was held by the USA.

Europe is anticipated to register high CAGR because of large-scale government initiatives to spread awareness about the disorder.

Asia Pacific is projected to register significant revenue in the global market owing to the emergence of multiple private market players aided by the presence of low-cost skilled labor, and improved research facilities.

Major players operating in the global erectile dysfunction drugs market include Eli Lilly & Co., Pfizer, Dong-A Pharmaceutical Co. Ltd, Bayer AG, Meda Pharmaceuticals, Vivus, Inc., and Apricus Biosciences.

Recent Developments:

• May 2020, Metuchen Pharmaceuticals, L.L.C., a privately owned biopharmaceutical aimed at defining, developing, gaining, and commercializing revolutionary therapeutics for male sexual health conditions, and Neurotrope, Inc. (“Neurotrope”) officially revealed that the two firms have decided to enter into a concise merger agreement within which Metuchen and Neurotrope, Inc. will unite in an all-stock purchase arising in a newly formed partnership firm (“Petros”). Petros is anticipated to become a Nasdaq-listed corporation specializing in men’s health.

Browse the full “Erectile Dysfunction Drugs Market By Therapeutics (Existing Drugs, Tadalafil, Sildenafil Citrate Vardenafil, Udenafil, Stendra/Spedra, Lodenafil Carbonate, Mirodenafil Pipeline Drugs, Apomorphine, Alprostadil, Topiglan, Gene Therapy, And Melanocortin Activators), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2022 – 2028.” Report at https://www.zionmarketresearch.com/report/erectile-dysfunction-drugs-market

Global erectile dysfunction drugs market is segmented as follows:

By Therapeutics

• Existing drugs
• Tadalafil
• Sildenafil Citrate Vardenafil
• Udenafil
• Stendra/Spedra
• Lodenafil Carbonate
• Mirodenafil Pipeline drugs
• Apomorphine
• Alprostadil
• Topiglan
• Gene Therapy
• Melanocortin Activators

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com